organization · Reporting owner
Vivo Opportunity Cayman, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | 10% owner | July 14, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date July 14, 2026 · Filed July 17, 2026
Jointly reported with Vivo Opportunity, LLC, Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman Fund, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Vivo Opportunity Fund Holdings, L.P. | 743,057 |
Last balance in matching sequence
After 2026-07-16 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-07-14 · Purchase · Acquired 4,882 · Balance 729,277 F1: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Row 3 · 2026-07-15 · Purchase · Acquired 13,761 · Balance 743,038 F1: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Row 5 · 2026-07-16 · Purchase · Acquired 19 · Balance 743,057 F1: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Common SharesSEC Table I · non-derivative | IndirectBy Vivo Opportunity Cayman Fund, L.P. | 75,019 |
Last balance in matching sequence
After 2026-07-16 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-07-14 · Purchase · Acquired 493 · Balance 73,628 F2: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Row 4 · 2026-07-15 · Purchase · Acquired 1,389 · Balance 75,017 F2: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Row 6 · 2026-07-16 · Purchase · Acquired 2 · Balance 75,019 F2: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 17, 2026 01:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 2 | $1.55 | $3.10 |
DisclosureSEC source: 0001213900-26-078891 · ownership.xml · nonDerivative · entry 6 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 75,019 F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 01:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 19 | $1.55 | $29.45 |
DisclosureSEC source: 0001213900-26-078891 · ownership.xml · nonDerivative · entry 5 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 743,057 F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 01:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 1,389 | $1.55 | $2,152.95 |
DisclosureSEC source: 0001213900-26-078891 · ownership.xml · nonDerivative · entry 4 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 75,017 F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 01:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 13,761 | $1.55 | $21,329.55 |
DisclosureSEC source: 0001213900-26-078891 · ownership.xml · nonDerivative · entry 3 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 743,038 F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 14, 2026 Filed Jul 17, 2026 01:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 493 | $1.55 | $764.15 |
DisclosureSEC source: 0001213900-26-078891 · ownership.xml · nonDerivative · entry 2 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 73,628 F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 14, 2026 Filed Jul 17, 2026 01:58 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 4,882 | $1.55 | $7,567.10 |
DisclosureSEC source: 0001213900-26-078891 · ownership.xml · nonDerivative · entry 1 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 729,277 F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 23:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 147 | $1.55 | $227.85 |
DisclosureSEC source: 0001213900-26-075144 · ownership.xml · nonDerivative · entry 6 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 73,135 F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 23:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 1,460 | $1.55 | $2,263.00 |
DisclosureSEC source: 0001213900-26-075144 · ownership.xml · nonDerivative · entry 5 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 724,395 F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 23:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 398 | $1.55 | $616.90 |
DisclosureSEC source: 0001213900-26-075144 · ownership.xml · nonDerivative · entry 4 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 72,988 F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 23:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 3,946 | $1.55 | $6,116.30 |
DisclosureSEC source: 0001213900-26-075144 · ownership.xml · nonDerivative · entry 3 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 722,935 F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 55 | $1.54 | $84.70 |
DisclosureSEC source: 0001213900-26-075144 · ownership.xml · nonDerivative · entry 2 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 72,590 F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:02 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 545 | $1.54 | $839.30 |
DisclosureSEC source: 0001213900-26-075144 · ownership.xml · nonDerivative · entry 1 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 718,989 F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 2,982 | $1.52 | $4,532.64 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 18 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 72,535 F11 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 29,518 | $1.52 | $44,867.36 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 17 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 718,444 F11 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 05, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 5,045 | $1.57 | $7,920.65 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 16 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 69,553 F10 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 05, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 49,966 | $1.57 | $78,446.62 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 15 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 688,926 F10 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 04, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 618 | $1.57 | $970.26 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 14 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 64,508 F9 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 04, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 6,125 | $1.57 | $9,616.25 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 13 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 638,960 F9 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 03, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 714 | $1.55 | $1,106.70 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 12 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 63,890 F8 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 03, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 7,069 | $1.55 | $10,956.95 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 11 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 632,835 F8 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 02, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 2,095 | $1.52 | $3,184.40 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 10 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 63,176 F7 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 02, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 20,753 | $1.52 | $31,544.56 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 9 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 625,766 F7 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 01, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 1,498 | $1.55 | $2,321.90 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 8 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 61,081 F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 01, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 14,838 | $1.55 | $22,998.90 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 7 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 605,013 F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 29, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 1,632 | $1.57 | $2,562.24 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 6 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 59,583 F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 29, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 16,164 | $1.57 | $25,377.48 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 5 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 590,175 F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 21, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 3,118 | $1.69 | $5,269.42 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 4 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 57,951 F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 21, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 30,882 | $1.69 | $52,190.58 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 3 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 574,011 F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 20, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 5,154 | $1.56 | $8,040.24 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 2 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Cayman Fund, L.P. Disclosed balance after: 54,833 F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 20, 2026 Filed Jun 11, 2026 01:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | PurchaseCommon Shares | 51,056 | $1.56 | $79,647.36 |
DisclosureSEC source: 0001213900-26-067505 · ownership.xml · nonDerivative · entry 1 Vivo Opportunity, LLC · CIK 0001728970 · 10% owner Vivo Opportunity Fund Holdings, L.P. · CIK 0001930214 · 10% owner Vivo Opportunity Cayman, LLC · CIK 0001930113 · 10% owner Vivo Opportunity Cayman Fund, L.P. · CIK 0001875722 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 543,129 F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F1 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.